Clinical trials: Pituitary Tumor
Leiomyoma, Laparoscopy
Combined Vaginal Misoprostol and Perivascular Vasopressin
Injection of Vasopressin into the uterine tissue surrounding fibroids constricts blood vessels, and has been found to be beneficial by decreasing blood flow to fibroids, and thereby resulting in less bleeding with removal.
- Conditions
- Leiomyoma, Laparoscopy, Uterine Myomectomy
- Trial name
- NCT03815344
- Testing
- Standard, Standard-vaginal misoprostol
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Antonios Likourezos
Anovulation, Oligo-ovulation
Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women
This is an open-label, parallel-group, randomized, multicenter Phase III trial to compare the efficacy and safety of a single 250 microgram (mcg) subcutaneous dose of MSJ-0011 to a single 5,000 international units (IU)…
- Conditions
- Anovulation, Oligo-ovulation, Hypothalamic-pituitary Dysfunction, Polycystic Ovarian Syndrome
- Trial name
- NCT01653743
- Testing
- MSJ-0011, urinary hCG (u-hCG), Follitropin alpha
- Where
- 6 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Recurrent Pituitary Adenomas
Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas
This is an open label study to assess the efficacy of capecitabine (CAP) and temozolomide (TMZ) in recurrent pituitary adenomas. There will be a safety run-in of at least three patients to establish any dose limiting toxicities.
- Trial name
- TMZ-Cap (NCT03930771)
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Pituitary Adenoma, Pituitary Diseases
Peri-Operative Steroid Management in Patients
During transsphenoidal resection of pituitary tumors and cysts, surgery is performed by a neurosurgeon and ear nose and throat surgeon.
- Trial name
- Steroid (NCT02084134)
- Testing
- hydrocortisone, dexamethasone
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Washington University School of Medicine
Osteopenia
Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density
The purpose of this project is to evaluate the hypothesis that bisphosphonate treatment given to growth hormone deficient patients (regardless of current growth hormone replacement therapy status and without changing that status)…
- Trial name
- NCT00145704
- Testing
- bisphosphonate therapy (risedronate), Vitamin D supplement, Calcium
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- State University of New York - Upstate Medical University
Acromegaly
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
If someone is diagnosed with a pituitary tumor that causes acromegaly (too much growth hormone) the treatment is to have it surgically removed. This study has two phases.
- Trial name
- NCT01861717
- Testing
- lanreotide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Saint John's Cancer Institute
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain
In 2014, the Spanish Sociedad Española de Oncología Médica (SEOM) algorithm for the treatment of hyponatraemia secondary to to syndrome of inappropriate antidiuretic hormone (SIADH) in oncology patients was developed.
- Trial name
- ALGA (NCT02548845)
- Where
- 4 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Acromegaly
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
- Trial name
- PAOLA (NCT01137682)
- Testing
- Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
- Where
- 60 sites in United States, Argentina and 16 more
- Volunteers
- 198 people
- Sponsor
- Novartis Pharmaceuticals
Pituitary Adenoma
Surgical Debulking of Pituitary Adenomas
This is a randomized, multicenter trial with stratification done by a single radiologist at the coordinating center (NYU), and patients with comparable disease will be randomized to Sandostatin LAR treatment administered 1 time…
- Trial name
- NCT01371643
- Testing
- Octreotide LAR, transsphenoidal surgery
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- NYU Langone Health
Cushing's Disease
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
This study provided access to pasireotide sc in patients with Cushing's disease.and provided additional information for safety and efficacy of pasireotide s.c.
- Trial name
- SEASCAPE (NCT01582061)
- Testing
- Pasireotide sub-cutaneous
- Where
- 65 sites in United States, Brazil and 9 more
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly, Neuroendocrine Tumors
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid…
- Trial name
- NCT02299089
- Testing
- octreotide FluidCrystal® injection depot
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Camurus AB
Cushing's Disease
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
RATIONALE: Rosiglitazone may help pituitary tumor cells become more like normal cells, and to grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly…
- Trial name
- NCT00612066
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Healthy, Pituitary Disease
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
This study will determine the safety and activity of a new formulation of thyrotropin-releasing hormone (TRH), a drug used for diagnosing and evaluating patients with certain thyroid gland abnormalities.
- Conditions
- Healthy, Pituitary Disease, Thyroid Disease
- Trial name
- NCT00054756
- Testing
- TRH (Thyrotropin Releasing Hormone)
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Gonadotroph Adenomas
Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum follicle-stimulating hormone…
- Trial name
- LAR (NCT00929669)
- Testing
- pasireotide LAR
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pennsylvania
Non-functioning Pituitary Adenoma
Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.
This study assessed pasireotide LAR efficacy on patients with non-functioning pituitary adenomas concerning tumor growth.
- Trial name
- Passion I (NCT01283542)
- Testing
- Pasireotide LAR
- Where
- 7 sites in Brazil
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Pituitary Tumor, Pain
Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors
A randomized, double-blind, placebo-controlled intervention trial involving 100 treated subjects undergoing endonasal trans-sphenoidal (ENTS) resection of pituitary lesion.
- Trial name
- NCT02351700
- Testing
- IV Caldolor
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Brain Tumor, Recurrent
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
This study will be aimed at investigating the effectiveness of a treatment for brain tumors called Photodynamic Therapy, or PDT.
- Trial name
- NCT01966809
- Testing
- Photofrin photodynamic therapy.
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Harry T Whelan, MD
Pancreatic Neoplasm, Pituitary Neoplasm
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
- Conditions
- Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
- Trial name
- NCT00958841
- Testing
- pasireotide LAR
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly, Pituitary Gigantism
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
To evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of pasireotide LAR in Japanese patients with active acromegaly or pituitary gigantism.
- Trial name
- NCT01673646
- Testing
- Pasireotide LAR
- Where
- 27 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals